CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: A Position Paper from the Fleischner society

The Lancet Respiratory Medicine

Volumn 3, Issue 6, 2015, Pages 483-496

  Hansell, David M ^a   Goldin, Jonathan G ^b   King, Talmadge E ^c   Lynch, David A ^d   Richeldi, Luca ^e   Wells, Athol U ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC PNEUMONITIS; BRONCHIECTASIS; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; IMAGE ANALYSIS; LUNG DIFFUSION CAPACITY; LUNG VOLUME; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVIEW; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; INTERSTITIAL LUNG DISEASE; LUNG; PRACTICE GUIDELINE; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX;

HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84930872707     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00096-X     Document Type: Review

References (120)

1. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2071-2082. the INPULSIS Trial Investigators.
2. King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092. the ASCEND Study Group.
3. Wells AU, Kokosi M, Karagiannis K Treatment strategies for idiopathic interstitial pneumonias. Curr Opin Pulm Med 2014, 20:442-448.
4. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248-1254.
5. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012, 156:684-691.
6. Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest 2014, 145:723-728.
7. Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 2008, 246:935-940.
8. Goldin JG Computed tomography as a biomarker in clinical trials imaging. J Thorac Imaging 2013, 28:291-297.
9. Saketkoo LA, Mittoo S, Huscher D, et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2014, 69:428-436. the CTD-ILD Special Interest Group.
10. Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013, 42:750-757.
11. Schmidt SL, Tayob N, Han MK, et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 2014, 145:579-585.
12. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013, 188:733-748. the ATS/ERS Committee on Idiopathic Interstitial Pneumonias.
13. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168:531-537.
14. Peelen L, Wells AU, Prijs M, et al. Fibrotic idiopathic interstitial pneumonias: mortality is linked to a decline in gas transfer. Respirology 2010, 15:1233-1243.
15. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003, 167:962-969.
16. King TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001, 164:1171-1181.
17. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006, 174:803-809.
18. Eaton T, Young P, Milne D, Wells AU Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005, 171:1150-1157.
19. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011, 183:1231-1237.
20. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824. the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis.
21. Wells AU Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear. Thorax 2013, 68:309-310.
22. Austin JHM, Müller NL, Friedman PJ, et al. Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleischner Society. Radiology 1996, 200:327-331.
23. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008, 246:697-722.
24. Watadani T, Sakai F, Johkoh T, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 2013, 266:936-944.
25. Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005, 172:488-493. the Idiopathic Pulmonary Fibrosis Study Group.
26. Walsh SL, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2014, 69:216-222.
27. Edey AJ, Devaraj AA, Barker RP, Nicholson AG, Wells AU, Hansell DM Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Eur Radiol 2011, 21:1586-1593.
28. Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med 2008, 177:433-439.
29. Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997, 169:977-983.
30. Sundaram B, Gross BH, Oh E, Müller N, Myles JD, Kazerooni EA Reader accuracy and confidence in diagnosing diffuse lung disease on high-resolution computed tomography of the lungs: impact of sampling frequency. Acta Radiol 2008, 49:870-875.
31. Winklehner A, Berger N, Maurer B, Distler O, Alkadhi H, Frauenfelder T Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. Ann Rheum Dis 2012, 71:549-552.
32. Sverzellati N, Devaraj A, Desai SR, Quigley M, Wells AU, Hansell DM Method for minimizing observer variation for the quantitation of high-resolution computed tomographic signs of lung disease. J Comput Assist Tomogr 2011, 35:596-601.
33. Silva CI, Müller NL, Hansell DM, Lee KS, Nicholson AG, Wells AU Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time. Radiology 2008, 247:251-259.
34. Akira M, Sakatani M, Ueda E Idiopathic pulmonary fibrosis: progression of honeycombing at thin-section CT. Radiology 1993, 189:687-691.
35. Jeong YJ, Lee KS, Müller NL, et al. Usual interstitial pneumonia and non-specific interstitial pneumonia: serial thin-section CT findings correlated with pulmonary function. Korean J Radiol 2005, 6:143-152.
36. Iwasawa T, Ogura T, Sakai F, et al. CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. Eur J Radiol 2014, 83:32-38.
37. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007, 176:636-643. the Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators.
38. Kim EA, Johkoh T, Lee KS, et al. Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation. J Comput Assist Tomogr 2001, 25:757-763.
39. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2229-2242. the IFIGENIA Study Group.
40. Lloyd CR, Walsh SL, Hansell DM High-resolution CT of complications of idiopathic fibrotic lung disease. Br J Radiol 2011, 84:581-592.
41. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005, 142:963-967. the IPF Study Group.
42. Hartley PG, Galvin JR, Hunninghake GW, et al. High-resolution CT-derived measures of lung density are valid indexes of interstitial lung disease. J Appl Physiol (1985) 1994, 76:271-277.
43. Best AC, Lynch AM, Bozic CM, Miller D, Grunwald GK, Lynch DA Quantitative CT indexes in idiopathic pulmonary fibrosis: relationship with physiologic impairment. Radiology 2003, 228:407-414.
44. Sverzellati N, Calabrò E, Chetta A, et al. Visual score and quantitative CT indices in pulmonary fibrosis: Relationship with physiologic impairment. Radiol Med (Torino) 2007, 112:1160-1172.
45. Iwasawa T, Asakura A, Sakai F, et al. Assessment of prognosis of patients with idiopathic pulmonary fibrosis by computer-aided analysis of CT images. J Thorac Imaging 2009, 24:216-222.
46. Maldonado F, Moua T, Rajagopalan S, et al. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J 2014, 43:204-212.
47. Zavaletta VA, Bartholmai BJ, Robb RA High resolution multidetector CT-aided tissue analysis and quantification of lung fibrosis. Acad Radiol 2007, 14:772-787.
48. Uppaluri R, Hoffman EA, Sonka M, Hartley PG, Hunninghake GW, McLennan G Computer recognition of regional lung disease patterns. Am J Respir Crit Care Med 1999, 160:648-654.
49. Kim HJ, Li G, Gjertson D, et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol 2008, 15:1004-1016.
50. Kim HJ, Brown MS, Elashoff R, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol 2011, 21:2455-2465.
51. Coxson HO Sources of variation in quantitative computed tomography of the lung. J Thorac Imaging 2013, 28:272-279.
52. Van Dyk J, Keane TJ, Rider WD Lung density as measured by computerized tomography: implications for radiotherapy. Int J Radiat Oncol Biol Phys 1982, 8:1363-1372.
53. Wegener OH, Koeppe P, Oeser H Measurement of lung density by computed tomography. J Comput Assist Tomogr 1978, 2:263-273.
54. Lamers RJ, Kemerink GJ, Drent M, van Engelshoven JM Reproducibility of spirometrically controlled CT lung densitometry in a clinical setting. Eur Respir J 1998, 11:942-945.
55. Robinson PJ, Kreel L Pulmonary tissue attenuation with computed tomography: comparison of inspiration and expiration scans. J Comput Assist Tomogr 1979, 3:740-748.
56. Kemerink GJ, Kruize HH, Lamers RJ, van Engelshoven JM Density resolution in quantitative computed tomography of foam and lung. Med Phys 1996, 23:1697-1708.
57. Kemerink GJ, Kruize HH, Lamers RJ, van Engelshoven JM CT lung densitometry: dependence of CT number histograms on sample volume and consequences for scan protocol comparability. J Comput Assist Tomogr 1997, 21:948-954.
58. Stoel BC, Bakker ME, Stolk J, et al. Comparison of the sensitivities of 5 different computed tomography scanners for the assessment of the progression of pulmonary emphysema: a phantom study. Invest Radiol 2004, 39:1-7.
59. Council Directive 97/43/Euratom of 30 June 1997 on health protection of individuals against the dangers of ionizing radiation in relation to medical exposure, and repealing Directive 84/466/Euratom. Off J Eur Communities 1997, L180:22. European Communities.
60. Naidich DP, Marshall CH, Gribbin C, Arams RS, McCauley DI Low-dose CT of the lungs: preliminary observations. Radiology 1990, 175:729-731.
61. Zwirewich CV, Mayo JR, Müller NL Low-dose high-resolution CT of lung parenchyma. Radiology 1991, 180:413-417.
62. Sverzellati N, Zompatori M, De Luca G, et al. Evaluation of quantitative CT indexes in idiopathic interstitial pneumonitis using a low-dose technique. Eur J Radiol 2005, 56:370-375.
63. Sverzellati N, Guerci L, Randi G, et al. Interstitial lung diseases in a lung cancer screening trial. Eur Respir J 2011, 38:392-400.
64. Bankier AA, Tack D Dose reduction strategies for thoracic multidetector computed tomography: background, current issues, and recommendations. J Thorac Imaging 2010, 25:278-288.
65. Baumueller S, Winklehner A, Karlo C, et al. Low-dose CT of the lung: potential value of iterative reconstructions. Eur Radiol 2012, 22:2597-2606.
66. Erbes R, Schaberg T, Loddenkemper R Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome?. Chest 1997, 111:51-57.
67. Ley B, Collard HR, King TE Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183:431-440.
68. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174:659-664.
69. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013, 309:2232-2239.
70. Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014, 190:906-913.
71. Han MK, Murray S, Fell CD, et al. Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J 2008, 31:1183-1188.
72. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006, 129:746-752.
73. King TE, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001, 164:1025-1032.
74. Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002, 166:173-177.
75. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998, 157:1063-1072.
76. Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012, 40:101-109.
77. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:459-466.
78. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338. the ATS/ERS Task Force.
79. Gruden JF, Panse PM, Leslie KO, Tazelaar HD, Colby TV UIP diagnosed at surgical lung biopsy, 2000-2009: HRCT patterns and proposed classification system. AJR Am J Roentgenol 2013, 200:W458-W467.
80. Chung JH, Chawla A, Peljto AL, et al. CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis. Chest 2015, 147:450-459.
81. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769. the CAPACITY Study Group.
82. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666. the Scleroderma Lung Study Research Group.
83. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002, 29:2371-2378.
84. Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002, 29:731-736.
85. Goldin J, Elashoff R, Kim HJ, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest 2009, 136:1333-1340.
86. Ingegnoli F, Lubatti C, Ingegnoli A, Boracchi P, Zeni S, Meroni PL Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 2012, 11:335-340.
87. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007, 175:705-711.
88. Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003, 167:1410-1415.
89. Kocheril SV, Appleton BE, Somers EC, et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 2005, 53:549-557.
90. Khanna D, Clements PJ, Furst DE, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum 2005, 52:592-600. the Scleroderma Lung Study Group.
91. Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009, 36:773-780. the Scleroderma Lung Study Research Group.
92. Sato S, Nagaoka T, Hasegawa M, Nishijima C, Takehara K Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis. Dermatology 2000, 200:196-201.
93. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010, 35:1322-1328.
94. Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009, 136:23-30.
95. Walsh SL, Sverzellati N, Devaraj A, Wells AU, Hansell DM Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol 2012, 22:1672-1679.
96. Khanna D, Brown KK, Clements PJ, et al. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol 2010, 28(suppl 58):S55-S62.
97. Baughman RP, Shipley R, Desai S, et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 2009, 136:526-535. the Sarcoidosis Investigators.
98. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996, 51:238-247.
99. Muers MF, Middleton WG, Gibson GJ, et al. A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the British Thoracic Society Study of long-term corticosteroid treatment. Sarcoidosis Vasc Diffuse Lung Dis 1997, 14:46-56.
100. Abehsera M, Valeyre D, Grenier P, Jaillet H, Battesti JP, Brauner MW Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. AJR Am J Roentgenol 2000, 174:1751-1757.
101. Akira M, Kozuka T, Inoue Y, Sakatani M Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest 2005, 127:185-191.
102. Zappala CJ, Desai SR, Copley SJ, et al. Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial high-resolution CT scan data. Chest 2014, 145:101-107.
103. Drent M, De Vries J, Lenters M, et al. Sarcoidosis: assessment of disease severity using HRCT. Eur Radiol 2003, 13:2462-2471.
104. Remy-Jardin M, Giraud F, Remy J, Wattinne L, Wallaert B, Duhamel A Pulmonary sarcoidosis: role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment. Radiology 1994, 191:675-680.
105. Leung AN, Brauner MW, Caillat-Vigneron N, Valeyre D, Grenier P Sarcoidosis activity: correlation of HRCT findings with those of 67Ga scanning, bronchoalveolar lavage, and serum angiotensin-converting enzyme assay. J Comput Assist Tomogr 1998, 22:229-234.
106. Bartz RR, Stern EJ Airways obstruction in patients with sarcoidosis: expiratory CT scan findings. J Thorac Imaging 2000, 15:285-289.
107. Davies CWH, Tasker AD, Padley SPG, Davies RJO, Gleeson FV Air trapping in sarcoidosis on computed tomography: correlation with lung function. Clin Radiol 2000, 55:217-221.
108. Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014, 2:123-130.
109. Chung JH, Little BP, Forssen AV, et al. Proton MRI in the evaluation of pulmonary sarcoidosis: comparison to chest CT. Eur J Radiol 2013, 82:2378-2385.
110. Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, et al. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med 2012, 53:1543-1549.
111. Mostard RL, Van Kuijk SM, Verschakelen JA, et al. A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis. BMC Pulm Med 2012, 12:57.
112. Mostard RL, Verschakelen JA, van Kroonenburgh MJ, et al. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med 2013, 107:439-447.
113. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007, 132:1949-1953.
114. Treglia G, Taralli S, Giordano A Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis 2011, 28:87-94.
115. Umeda Y, Demura Y, Morikawa M, et al. Prognostic value of dual-time-point 18F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis. Respirology 2011, 16:713-720.
116. Churg A, Sin DD, Everett D, Brown K, Cool C Pathologic patterns and survival in chronic hypersensitivity pneumonitis. Am J Surg Pathol 2009, 33:1765-1770.
117. Ohtani Y, Saiki S, Kitaichi M, et al. Chronic bird fancier's lung: histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 2005, 60:665-671.
118. Sahin H, Brown KK, Curran-Everett D, et al. Chronic hypersensitivity pneumonitis: CT features comparison with pathologic evidence of fibrosis and survival. Radiology 2007, 244:591-598.
119. Vourlekis JS, Schwarz MI, Cherniack RM, et al. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med 2004, 116:662-668.
120. Hanak V, Golbin JM, Hartman TE, Ryu JH High-resolution CT findings of parenchymal fibrosis correlate with prognosis in hypersensitivity pneumonitis. Chest 2008, 134:133-138.